IP Library › Patent Application 13336294
Patent Application
App. No. 13/336,294

Tat-Based Tolerogen Compositions and Methods for Making and Using Same

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/336,294
Abstract

A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided.

Claims (16)

1 . A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule.

2 . The Tat-based tolerogen composition of claim 1 wherein the immunogenic antigen is a foreign antigen or an endogenous antigen.

3 . The Tat-based tolerogen composition of claim 1 wherein the immunogenic antigen comprises a full length protein or a fragment thereof.

4 . The Tat-based tolerogen composition of claim 1 wherein the immunogenic antigen is insulin or portions thereof.

5 . The Tat-based tolerogen composition of claim 1 wherein the immunogenic antigen is a monoclonal antibody or portions thereof.

6 . The Tat-based tolerogen composition of claim 1 wherein the immunogenic antigen is Factor VIII or portions thereof.

7 . The Tat-based tolerogen composition of claim 1 wherein the immunogenic antigen is a carbohydrate antigen.

8 . The Tat-based tolerogen composition of claim 1 wherein the Tat protein and the immunogenic antigen are physically linked via a protein conjugation method.

9 . The Tat-based tolerogen composition of claim 1 wherein the Tat protein and the immunogenic antigen are linked through genetic engineering of their DNA to provide a recombinant protein.

10 . A method for suppressing organ transplant rejection comprising administering at least one Tat-based tolerogen composition to a patient in need of an organ transplant.

11 . The method for suppressing organ transplant rejection according to claim 10 comprising perfusing the organ with the Tat-based tolerogen composition.

12 . The method for suppressing organ transplant rejection according to claim 10 comprising implanting a device saturated with the Tat-based tolerogen composition wherein the Tat-based tolerogen composition is released into a transplanted organ.

13 . The method for suppressing organ transplant rejection according to claim 11 additionally comprising implanting a device saturated with the Tat-based tolerogen composition wherein the Tat-based tolerogen composition is released into a transplanted organ.

14 . A method for reducing inflammation comprising administering at least one Tat-based tolerogen composition to a patient in need thereof.

15 . The method according to claim 14 wherein the inflammation is associated with an autoimmune disease and the method comprises administering at least one Tat-based tolerogen composition to a patient having an autoimmune disease.

16 . The method according to claim 15 wherein the autoimmune disease is rheumatoid arthritis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2011
From: NANIRX THERAPEUTICS, INC.
To: PIN PHARMA, INC.
Reel/Frame 027467/0136 →